加载中
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
收盘时
US$2.90
−US$0.20 · -6.45%
盘后
US$2.93
+US$0.03 · +1.03%
10月12日 17:05 ET
盘中时间采用ET。市场数据可能有所延迟。
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
日内区间
当前US$2.90
52周区间
当前US$2.90
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
65
低估
情绪
59
多空交织
风险
85
极高风险
动量
21
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
日内区间
当前US$2.90
52周区间
当前US$2.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | — | 8.6万 USD | 1.2万 USD | — | 78.52万 USD |
| 销货成本 | 24万 USD | 24.6万 USD | 10.3万 USD | — | 6335 USD |
| 毛利 | −24万 USD | −16万 USD | 1.2万 USD | — | 77.88万 USD |
| 研究与开发 | 521万 USD | 1074.7万 USD | 1928.12万 USD | 949.57万 USD | 537.13万 USD |
| 销售、一般及管理费用 | 1781.7万 USD | 1312.8万 USD | 2555.7万 USD | 1192.65万 USD | 1017.87万 USD |
| 营业费用 | 2278.7万 USD | 2362.9万 USD | 3005.3万 USD | 2052.66万 USD | 1212.67万 USD |
| 利息收入 | 2.1万 USD | 6.2万 USD | 30.84万 USD | 36.27万 USD | 6269 USD |
| 利息支出 | — | 30.3万 USD | — | — | — |
| 折旧和摊销 | 24万 USD | 24.6万 USD | 10.3万 USD | 13.24万 USD | 1135.07万 USD |
| 营业利润 | −2302.7万 USD | −2378.9万 USD | −3004.1万 USD | −2052.66万 USD | −1135.07万 USD |
| 净利润 | −1930.2万 USD | −4688.5万 USD | −1845.9万 USD | −7346.58万 USD | −1490.23万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
